(5 R)-5-Hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation

A novel triptolide derivative (5 R)-5-hydroxytriptolide (LLDT-8) has been shown to have potent immunosuppressive activities. Here LLDT-8 was evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS). LLDT-8 reduced the incidence and severity of EAE, which was...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2006-06, Vol.175 (1), p.142-151
Main Authors: Fu, Yun-Feng, Zhu, Yi-Na, Ni, Jia, Zhong, Xiang-Gen, Tang, Wei, Zhou, Ru, Zhou, Yu, Dong, Jia-Rong, He, Pei-Lan, Wan, Hua, Li, Yuan-Chao, Yang, Yi-Fu, Zuo, Jian-Ping
Format: Article
Language:English
Subjects:
(5 R)-5-Hydroxytriptolide
Amino Acid Sequence
Animals
Cell Proliferation - drug effects
Cytokine
Diterpenes - administration & dosage
Diterpenes - chemistry
Diterpenes - pharmacology
Diterpenes - therapeutic use
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - prevention & control
Epoxy Compounds
Experimental autoimmune encephalomyelitis
Female
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
Lymphocyte Activation - drug effects
Lymphocyte Activation - physiology
Mice
Mice, Inbred C57BL
Molecular Sequence Data
Phenanthrenes - administration & dosage
Phenanthrenes - pharmacology
Phenanthrenes - therapeutic use
T cell
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel triptolide derivative (5 R)-5-hydroxytriptolide (LLDT-8) has been shown to have potent immunosuppressive activities. Here LLDT-8 was evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS). LLDT-8 reduced the incidence and severity of EAE, which was associated with the inhibition of the MOG 35–55 lymphocyte recall response, anti-MOG 35–55 T cell responses, interleukin (IL)-2 and interferon (IFN)-γ production. In vitro, LLDT-8 inhibited primary T cells proliferation, division, IL-2 and IFN-γ production stimulated with anti-CD3/28. These findings highlight the fact that LLDT-8 prevents EAE by suppressing T cell proliferation and activation, with a potential for treatment of MS.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2006.03.011